secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cryoport, Inc. (CYRX)
CIK:        0001124524
Form:       8-K
Filed at:   2023-07-12T23:59:59+00:00
Accession:  0001104659-23-080348
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cryoport expects Q2 revenue down 11% YoY; slashes FY2023 guidance to $233M-$243M
--------------------------------------------------------------------------------

- Preliminary Q2 revenue $56.5M-$57.5M, down ~11% YoY; weak capital equipment demand.
- FY2023 revenue guidance revised to $233M-$243M due to slower client ramps and trial delays.
- Q2 impact from weaker global demand for capital equipment and clinical trial start delays.
- CEO expects challenging conditions to persist into Q3 and Q4 2023.
- Long-term outlook remains robust as cell and gene therapy industry CAGR expected >22%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124524/000110465923080348/0001104659-23-080348-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124524/000110465923080348/tm2321174d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-080348

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer